ClinicalTrials.gg
Not yet recruitingNCT07003815Updated Jun 4, 2025

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

A Phase 2 interventional study of Envafolimab + Gemcitabine + Cisplatin + Simvastatin in Biliary Tract Cancer and Advanced Cancer, sponsored by Tongji Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Tongji Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing gemcitabine in Biliary Tract Neoplasms — 9 open to participants now, 13 under way, 2 of them phase 3. Gemcitabine · Biliary Tract Neoplasms.

Planned enrollment
18th of 49
62 · median 44
Started
2025
the only one that year
Phase 2
28 of 49
4 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
47th of 49
by date

Among the 49 studies testing gemcitabine in Biliary Tract Neoplasms, this one is the 18th largest by planned enrollment, is the only one that started in 2025, is one of 28 in phase 2, reaches primary completion later than 5 of the 12 other live ones, and was the 47th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

9 of the 49 studies testing gemcitabine in Biliary Tract Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing gemcitabine in Biliary Tract Neoplasms, or all of them as a file.
02

Study summary

Brief Summary

The goal of this clinical trial is to test whether the combination of Envafolimab (an immunotherapy drug), chemotherapy (gemcitabine + cisplatin), and simvastatin can help treat advanced biliary tract cancer (BTC) that cannot be removed by surgery or has spread. The study will also evaluate the safety of this treatment combination.

Key Questions Does the combination treatment help shrink tumors or slow cancer growth better than standard options? What side effects do participants experience with this treatment?

What Will Participants Do? Receive Envafolimab (IV infusion) + gemcitabine/cisplatin (chemotherapy) + simvastatin (oral pill) every 3 weeks for up to 8 cycles (\~6 months).

After 8 cycles, continue with Envafolimab + simvastatin alone every 4 weeks until cancer worsens or side effects become too severe.

Undergo regular scans, blood tests, and clinic visits to monitor tumor response and safety.

03

Conditions studied

  • Biliary Tract Cancer
  • Advanced Cancer

Keywords

  • Biliary Tract Cancer
  • Envafolimab
  • Simvastatin
  • Immunotherapy
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age : ≥18 years old.
  • Diagnosis : confirmed unresectable, locally advanced, or biliary tract adenocarcinoma (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer).
  • Prior Treatment :Treatment-naïve for unresectable/metastatic disease at initial diagnosis, OR Disease recurrence ≥6 months after curative surgery or therapy.
  • Performance Status : PS 0 or 1.
  • : At least one radiologically measurable lesion per 1.1 (tumor lesion ≥10 mm on CT scan, lymph node ≥15 mm in short axis).
  • Organ Function : No severe functional impairment of heart, lung, brain, or other vital organs.

Exclusion criteria

Exclusion Criteria:

  • Disease Type : Ampulla of Vater cancer.
  • Disease : Active or previously documented autoimmune/inflammatory disorders.
  • Allergy : to any study drug (Envafolimab, gemcitabine, cisplatin, or simvastatin).
  • Liver Function : Decompensated liver dysfunction.
  • Psychiatric History : Severe psychiatric disorders.
  • Recent Trials : Participation in other drug/device trials within 4 weeks prior to enrollment.
  • Compliance : Inability to adhere to protocol requirements or follow-up schedule.
  • Investigator's Discretion : Any other condition deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Envafolimab + Gemcitabine/Cisplatin + Simvastatin Combination Therapy

    Intervention(s): All enrolled participants will receive the following combination therapy: Envafolimab (300 mg, intravenous infusion, Day 1 of each 21-day cycle) - a PD-L1 inhibitor immunotherapy. Gemcitabine (1,000 mg/m², IV, Days 1 and 8 of each cycle) + Cisplatin (25 mg/m², IV, Days 1 and 8 of each cycle) - standard chemotherapy regimen. Simvastatin (40 mg, oral daily) - repurposed as a potential synergistic agent. Treatment Schedule: Initial Phase (Cycles 1-8): 21-day cycles for up to 8 cycles (≈6 months). Drugs administered as above. Maintenance Phase (Post-Cycle 8): Continue Envafolimab (300 mg, IV, every 28 days) + Simvastatin (40 mg, oral daily) until disease progression or unacceptable toxicity.

    Drug: Envafolimab + Gemcitabine + Cisplatin + Simvastatin

Interventions

  • DrugEnvafolimab + Gemcitabine + Cisplatin + Simvastatin

    Drug pages: EnvafolimabStudies of EnvafolimabEnvafolimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Envafolimab (generic name): Dose: 300 mg, intravenous (IV) infusion. Schedule: Day 1 of each 21-day cycle (induction phase); every 28 days (maintenance phase). Role: PD-L1 inhibitor immunotherapy. Gemcitabine (generic name): Dose: 1,000 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only). Cisplatin (generic name): Dose: 25 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only). Simvastatin (generic name): Dose: 40 mg, oral tablet. Schedule: Daily (continuously through induction and maintenance phases). Investigational Role: Potential immunomodulator and chemosensitizer in biliary tract cancer. Treatment Phases: Induction Phase (Cycles 1-8, 21-day cycles): All four drugs administered. Maintenance Phase (Post-Cycle 8): Envafolimab + Simvastatin only (28-day cycles).

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) at 24 Weeks

    Proportion of participants achieving complete response (CR) or partial response (PR) per RECIST 1.1 criteria, assessed by CT/MRI scans after 24 weeks of treatment. CR: disappearance of all target lesions; PR: ≥30% decrease in target lesion diameters.

    Time frame: From treatment initiation until 24 weeks (or disease progression, if earlier).

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time from treatment start to disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.

    Time frame: Up to 2 years.

  2. Overall Survival (OS)

    Time from treatment start to death from any cause.

    Time frame: Up to 2 years.

  3. Disease Control Rate (DCR)

    Proportion of participants with CR, PR, or stable disease (SD) lasting ≥12 weeks.

    Time frame: Up to 2 years.

  4. Duration of Response (DOR)

    Time from first documented response (CR/PR) to disease progression or death.

    Time frame: Up to 2 years.

  5. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Frequency and severity of adverse events graded by CTCAE v5.0.

    Time frame: From first dose until 30 days after last dose.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 18 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 4, 2025
StartEst.
Jun 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2028
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07003815
Lead sponsor
Tongji Hospital
Responsible party
Wan-Guang Zhang (Chief Physician, Tongji Hospital) — Principal investigator
First posted
Jun 4, 2025
Start date
Jun 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jun 4, 2025

Study contacts

Wanguang Prof. Zhang, M.D.
Contact
wgzhang@tjh.tjmu.edu.cn
+8613636076910

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Envafolimab · Gemcitabine · Cisplatin · Simvastatin

Start the discussion